ArticleFrontiers in oncology2025

Trastuzumab deruxtecan (DS-8201) plus bevacizumab for HER2-low metastatic breast cancer with malignant pleural effusion: a case report and literature review.

Hao Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.